Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Papulopustular Rosacea Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject has papulopustular rosacea with an Investigator Global Assessment (IGA) score rated 3 (moderate) or 4 (severe),~2. The subject has at least 15 but not more than 70 inflammatory lesions (papules and pustules) on the face.~Exclusion Criteria:~1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other facial dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, facial keratosis pilaris, seborrheic dermatitis, and acne,~2. The subject has rosacea with more than two nodules on the face.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CD5024 (Type: EXPERIMENTAL): CD5024 1% Cream
- CD5024 Vehicle (Type: PLACEBO_COMPARATOR): CD5024 Vehicle Cream

Based on this trial design, predict the completion outcome and termination type (if applicable).